During Monday’s current trade, Exxon Mobil Corporation (NYSE:XOM)’s shares gained 1.41%, and is now trading at $85.49, as the company on last Monday, declared that it began production in the deepwater Gulf of Mexico at Hadrian South with facilities tied back to the nearby Lucius project, reducing additional infrastructure requirements.
Daily gross production from Hadrian South, ExxonMobil’s deepest subsea tie-back in nearly a mile and a half of water, is predictable to reach about 300 million cubic feet of gas and 3,000 barrels of liquids from two wells.
“Successful deepwater projects like this are a result of ExxonMobil’s disciplined project execution capabilities and commitment to developing quality resources using advanced technology,” said Neil W. Duffin, president of ExxonMobil Development Corporation.
Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania. It also manufactures and markets commodity petrochemicals, counting olefins, aromatics, polyethylene and polypropylene plastics, and specialty products; and transports and sells crude oil, natural gas, and petroleum products.
Mylan N.V. (NASDAQ:MYL)’s shares gained 0.92% during the current trading session Monday, and is now trading at $58.63, as the company on last Tuesday, declared the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis’ Exforge® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure aims.
Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg had U.S. sales of about $415.3 million for the 12 months ending December 31, 2014, according to IMS Health.
Presently, Mylan has 269 ANDAs pending FDA approval representing $104.1 billion in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $27.3 billion in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The corporation provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
During current trade, Comcast Corporation (NASDAQ:CMCSA)’s shares climbed 0.69%, and is now trading at $58.33, as Comcast Business today declared a noteworthy expansion of its multi-gigabit Ethernet service to three business parks in the Northern California towns of Pleasanton, Hayward and Fremont. The high-speed fiber-based network build outs together total close to $2 million in investment by Comcast in the East Bay, making accessible reliable Internet speeds to the more than 1,500 businesses in the community by offering reliable Internet speeds up to 20 times faster than traditional 1.5 Mbps DSL or T-1 service.
Together, the three parks serve a variety of industries, ranging from manufacturing to biotech to education to consumer products and services – businesses with ever-increasing data needs.
Companies such as Ceva Logistics and Impax Laboratories are among the more than 150 businesses presently leasing space at the collection of Business Parks along Huntwood Avenue in Hayward. Fremont’s Bayside Business Park boasts of over 1 million square feet and serves as home to more than 400 companies, such as BASF Corporation, Mentor Graphics, Volterra Semiconductor Corporation. Many of the buildings in the Business Park are owned and operated by ProLogis. Pleasanton Valley Business Park, which spans 60 acres and boasts more than 300 tenants, was built as a manufacturing park 40 years ago, but now serves tenants such as Allied Ventures, Mazda Motor of America, Nichotech and Quest Consulting, among many others.
Comcast Corporation operates as a media and technology corporation worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments.
Catamaran Corporation (NASDAQ:CTRX), during its Monday’s current trading session lost -0.09%, and is now trading at $59.21, as on last Wednesday, a leading provider of pharmacy benefit administration (PBM) services and technology, released its annual Informed Trends™ report – revealing that diabetes accounted for a major share of the raise in traditional drug trend. Diabetes had the highest trend of any top traditional therapeutic class at 21.1 percent. This was predominantly driven by raises in medication costs – with insulin alone accounting for 30 percent of the unit cost raise for traditional trend.
Overall commercial drug trend was 5.7 percent in 2014; more than double the 2.4 percent overall trend in 2013, primarily due to the raises in drug costs and new drugs entering the specialty market. Though specialty medications represented only one percent of claims, the category accounted for more than 28 percent of total drug costs. New-to-market hepatitis C therapies had a strong influence on drug mix – the most noteworthy driver of specialty drug trend.
Catamaran has already demonstrated success in driving adherence to costly medication therapies through its specialty pharmacy, BriovaRx®. The specialty pharmacy has stated 9.1 percent better adherence rates among its hepatitis C patients, when contrast to those treated at non-BriovaRx pharmacies.
Catamaran Corporation provides pharmacy benefit administration (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits administration industry in North America. The corporation operates in two segments, PBM and HCIT.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
